Literature DB >> 20709632

Cyclooxygenase-independent inhibitory effects on T cell activation of novel 4,5-dihydro-3 trifluoromethyl pyrazole cyclooxygenase-2 inhibitors.

Miguel A Iñiguez1, Carmen Punzón, Cristina Cacheiro-Llaguno, Manuel D Díaz-Muñoz, Javier Duque, Rosa Cuberes, Inés Alvarez, Eva M Andrés, Jordi Buxens, Helmut Buschmann, José M Vela, Manuel Fresno.   

Abstract

Anti-inflammatory efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) has been related to their properties as inhibitors of cyclooxygenase (COX)-mediated prostaglandin (PG) synthesis. However, recent studies have suggested that variations of the in vivo anti-inflammatory actions among different NSAIDs could not be solely explained by COX inhibition. Here, we have analyzed the effects on T cell activation of novel 4,5-dihydro-3 trifluoromethyl pyrazole anti-inflammatory drugs with different potencies as COX-2 inhibitors, namely E-6087, E-6232, E-6231, E-6036 and E-6259 as well as the chemically related COX-2 inhibitor Celecoxib. These drugs inhibited mitogen-mediated T cell proliferation as well as Interleukin (IL)-2, tumor necrosis factor (TNF)-α and Interferon (IFN)-γ synthesis by activated T cells, independently of their ability to inhibit COX-2 enzymatic activity. Immunosuppressive effects of these drugs seem to be due to their interference on transcription factor activation as induced transcription from Nuclear Factor (NF)-κB and Nuclear Factor of Activated T cells (NFAT)-dependent enhancers was inhibited in a dose-dependent manner, being the latter effect the most sensitive to the action of those compounds. Both NFAT dephosphorylation, required for its nuclear translocation, as well as transcriptional activity of a GAL4-NFAT chimera were diminished in the presence of these compounds. These findings provide new insights into the molecular mechanisms involved in the immunomodulatory and anti-inflammatory actions of NSAIDs, which may have important implications in anti-inflammatory therapy, through inhibition of NFAT.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709632     DOI: 10.1016/j.intimp.2010.07.013

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  8 in total

1.  Effect of Early and Prophylactic Nonsteroidal Anti-Inflammatory Drugs on Flare Duration in Pediatric Acute-Onset Neuropsychiatric Syndrome: An Observational Study of Patients Followed by an Academic Community-Based Pediatric Acute-Onset Neuropsychiatric Syndrome Clinic.

Authors:  Kayla D Brown; Cristan Farmer; G Mark Freeman; Ellen J Spartz; Bahare Farhadian; Margo Thienemann; Jennifer Frankovich
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-07-11       Impact factor: 2.576

2.  Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E(2) production.

Authors:  Adam Mor; Elizabeta Aizman; Yoel Kloog
Journal:  Inflammation       Date:  2012-10       Impact factor: 4.092

3.  Long-term safety evaluation of Daxocox® tablets (enflicoxib) in dogs after weekly oral administrations for seven months.

Authors:  Josep Homedes; Marta Salichs; Antonio Guzman
Journal:  BMC Vet Res       Date:  2021-06-03       Impact factor: 2.741

4.  Pharmacology of enflicoxib, a new coxib drug: Efficacy and dose determination by clinical and pharmacokinetic-guided approach for the treatment of osteoarthritis in dogs based on an acute arthritis induction model.

Authors:  Josep-Maria Cendrós; Marta Salichs; Gregorio Encina; Jose Miguel Vela; Josep M Homedes
Journal:  Vet Med Sci       Date:  2021-12-02

5.  Comparative In vitro Metabolism of Enflicoxib in Dogs, Rats, and Humans: Main Metabolites and Proposed Metabolic Pathways.

Authors:  Josep Solà; Àngel Menargues; Josep Homedes; Marta Salichs; Maria Teresa Serafini; Gregorio Encina
Journal:  Drug Metab Lett       Date:  2021

6.  Selective inhibition of cyclooxygenase-2 by enflicoxib, its enantiomers and its main metabolites in vitro in canine blood.

Authors:  Josep Solà; Àngel Menargues; Josep Homedes; Marta Salichs; Inés Álvarez; Luz Romero; José Miguel Vela
Journal:  J Vet Pharmacol Ther       Date:  2022-01-17       Impact factor: 1.567

7.  Cyclooxygenase-2 and Prostaglandin E2 Signaling through Prostaglandin Receptor EP-2 Favor the Development of Myocarditis during Acute Trypanosoma cruzi Infection.

Authors:  Néstor A Guerrero; Mercedes Camacho; Luis Vila; Miguel A Íñiguez; Carlos Chillón-Marinas; Henar Cuervo; Cristina Poveda; Manuel Fresno; Núria Gironès
Journal:  PLoS Negl Trop Dis       Date:  2015-08-25

8.  Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration.

Authors:  Josep Homedes; Marta Salichs; Josep Solà; Angel Menargues; Josep-Maria Cendrós; Gregorio Encina
Journal:  J Vet Pharmacol Ther       Date:  2021-06-23       Impact factor: 1.567

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.